ceo kevin gorman rejoining us now. good to chat with you. go, chargers.the trial results. the last trial results you had, your stock rose after we interviewed you, then fell dramatically, the last trial results you had were unsuccessful. what did you change to make these work? >> thank you very much for having me on, brian. we changed a number of things. phase two clinical trials is a learning process for any biopharmaceutical company. you just happened to do it on the big stage here in front of the entire world. we had many learnings from that first trial, we changed slightly the clinical end point that we were using and we changed slightly from how the end point is applied, meaning the physicians at the clinical trial site is the way it was first done. we learned it's better to use central reading by movement disorder specialists in this trial. those two changes led to the dramatic effect that we see of the drug in this particular trial. >> just to reiterate here, this is for involuntary movement disorder. when do you think you might be able to finally